The drugmaker has settled a series of lawsuits related to Zantac over the past 12 months, including several in California.
In a joint report published on Monday, analysts estimated the market for obesity treatments could expand to $200 billion by ...
The report is based on insights from multiple interviews of global lifesciences leaders about their GenAI journey, primary ...
The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...
By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.
BI 771716, developed by Boehringer Ingelheim with technology licensed from CDR-Life. (Image Credits: Pixabay) Boehringer Ingelheim and CDR-Life on Monday announced positive results from the phase ...
Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase 3 win for a potentially first-in-class candidate and outlining plans to ...
With new phase 3 data in hand, Boehringer Ingelheim is preparing to file for approval of nerandomilast, a would-be successor to its blockbuster idiopathic pulmonary fibrosis (IPF) therapy Ofev.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback